1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	examined	_	_	VBD	_	_	_	_	_
4	whether	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	combined	_	_	VBN	_	_	_	_	_
7	administration	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	6.0	_	_	CD	_	_	_	_	_
10	g	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	glycine	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	0.4	_	_	CD	_	_	_	_	_
15	g	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	tryptophan	_	_	NN	_	_	_	_	_
18	suppressed	_	_	VBD	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	elevation	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	serum	_	_	NN	_	_	_	_	_
23	uric	_	_	JJ	_	_	_	_	_
24	acid	_	_	NN	_	_	_	_	_
25	levels	_	_	NNS	_	_	_	_	_
26	induced	_	_	VBN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	purine	_	_	NN	_	_	_	_	_
29	ingestion	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	increased	_	_	VBD	_	_	_	_	_
32	urinary	_	_	JJ	_	_	_	_	_
33	uric	_	_	NN	_	_	_	_	_
34	acid	_	_	NN	_	_	_	_	_
35	excretion	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	amino	_	_	JJ	_	_	_	_	_
3	acid	_	_	NN	_	_	_	_	_
4	doses	_	_	NNS	_	_	_	_	_
5	used	_	_	VBN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	single	_	_	JJ	_	_	_	_	_
8	ingestion	_	_	NN	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	based	_	_	VBN	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	those	_	_	DT	_	_	_	_	_
13	used	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	continual	_	_	JJ	_	_	_	_	_
16	supplementation	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Both	_	_	DT	_	_	_	_	_
2	glycine	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	tryptophan	_	_	NN	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	present	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	dietary	_	_	JJ	_	_	_	_	_
9	proteins	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	ingested	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	normal	_	_	JJ	_	_	_	_	_
15	daily	_	_	JJ	_	_	_	_	_
16	living	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	glycine	_	_	NN	_	_	_	_	_
4	at	_	_	IN	_	_	_	_	_
5	doses	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	up	_	_	IN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	90	_	_	CD	_	_	_	_	_
10	g	_	_	NNS	_	_	_	_	_
11	per	_	_	IN	_	_	_	_	_
12	day	_	_	NN	_	_	_	_	_
13	administered	_	_	VBN	_	_	_	_	_
14	over	_	_	IN	_	_	_	_	_
15	several	_	_	JJ	_	_	_	_	_
16	weeks	_	_	NNS	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	reported	_	_	VBN	_	_	_	_	_
19	no	_	_	DT	_	_	_	_	_
20	serious	_	_	JJ	_	_	_	_	_
21	adverse	_	_	JJ	_	_	_	_	_
22	effects	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	oral	_	_	JJ	_	_	_	_	_
3	administration	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	up	_	_	IN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	5.0	_	_	CD	_	_	_	_	_
8	g	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	l-tryptophan	_	_	NN	_	_	_	_	_
11	per	_	_	IN	_	_	_	_	_
12	day	_	_	NN	_	_	_	_	_
13	did	_	_	VBD	_	_	_	_	_
14	not	_	_	RB	_	_	_	_	_
15	lead	_	_	VB	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	any	_	_	DT	_	_	_	_	_
18	adverse	_	_	JJ	_	_	_	_	_
19	effects	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	young	_	_	JJ	_	_	_	_	_
22	adult	_	_	JJ	_	_	_	_	_
23	females	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	adverse	_	_	JJ	_	_	_	_	_
5	effects	_	_	NNS	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	attributed	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	combined	_	_	VBN	_	_	_	_	_
11	administration	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	glycine	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	tryptophan	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	current	_	_	JJ	_	_	_	_	_
19	trial	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	confirmed	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	safety	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	combined	_	_	VBN	_	_	_	_	_
8	glycine	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	tryptophan	_	_	NN	_	_	_	_	_
11	supplementation	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	current	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	demonstrated	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	combined	_	_	VBN	_	_	_	_	_
8	administration	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	glycine	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	tryptophan	_	_	NN	_	_	_	_	_
13	significantly	_	_	RB	_	_	_	_	_
14	suppressed	_	_	VBD	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	elevation	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	serum	_	_	NN	_	_	_	_	_
20	uric	_	_	NN	_	_	_	_	_
21	acid	_	_	NN	_	_	_	_	_
22	levels	_	_	NNS	_	_	_	_	_
23	caused	_	_	VBN	_	_	_	_	_
24	by	_	_	IN	_	_	_	_	_
25	purine	_	_	NN	_	_	_	_	_
26	ingestion	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	healthy	_	_	JJ	_	_	_	_	_
29	subjects	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	effect	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	combined	_	_	VBN	_	_	_	_	_
6	amino	_	_	JJ	_	_	_	_	_
7	acid	_	_	NN	_	_	_	_	_
8	administration	_	_	NN	_	_	_	_	_
9	was	_	_	VBD	_	_	_	_	_
10	stronger	_	_	JJR	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	that	_	_	DT	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	same	_	_	JJ	_	_	_	_	_
16	glycine	_	_	NN	_	_	_	_	_
17	dose	_	_	NN	_	_	_	_	_
18	alone	_	_	RB	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	indicating	_	_	VBG	_	_	_	_	_
21	that	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	small	_	_	JJ	_	_	_	_	_
24	amount	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	tryptophan	_	_	NN	_	_	_	_	_
27	provides	_	_	VBZ	_	_	_	_	_
28	an	_	_	DT	_	_	_	_	_
29	additional	_	_	JJ	_	_	_	_	_
30	benefit	_	_	NN	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	glycine	_	_	NN	_	_	_	_	_
33	alone	_	_	RB	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	reducing	_	_	VBG	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	elevation	_	_	NN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	serum	_	_	NN	_	_	_	_	_
41	uric	_	_	NN	_	_	_	_	_
42	acid	_	_	NN	_	_	_	_	_
43	levels	_	_	NNS	_	_	_	_	_
44	after	_	_	IN	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	ingestion	_	_	NN	_	_	_	_	_
47	of	_	_	IN	_	_	_	_	_
48	dietary	_	_	NN	_	_	_	_	_
49	purines	_	_	NNS	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	agreement	_	_	NN	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	previous	_	_	JJ	_	_	_	_	_
5	reports	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	glycine	_	_	NN	_	_	_	_	_
8	increased	_	_	VBD	_	_	_	_	_
9	urinary	_	_	JJ	_	_	_	_	_
10	uric	_	_	NN	_	_	_	_	_
11	acid	_	_	NN	_	_	_	_	_
12	excretion	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	enhanced	_	_	VBD	_	_	_	_	_
15	urate	_	_	NN	_	_	_	_	_
16	clearance	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	current	_	_	JJ	_	_	_	_	_
20	study	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	authors	_	_	NNS	_	_	_	_	_
3	previously	_	_	RB	_	_	_	_	_
4	reported	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	continual	_	_	JJ	_	_	_	_	_
7	supplementation	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	glycine	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	tryptophan	_	_	NN	_	_	_	_	_
12	led	_	_	VBD	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	increase	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	urinary	_	_	JJ	_	_	_	_	_
18	pH	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Glycine	_	_	NNP	_	_	_	_	_
2	exhibits	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	buffering	_	_	VBG	_	_	_	_	_
5	action	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	often	_	_	RB	_	_	_	_	_
10	used	_	_	VBN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	an	_	_	DT	_	_	_	_	_
13	antacid	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	water	_	_	NN	_	_	_	_	_
3	solubility	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	uric	_	_	NN	_	_	_	_	_
6	acid	_	_	NN	_	_	_	_	_
7	increases	_	_	VBZ	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	increasing	_	_	VBG	_	_	_	_	_
10	pH	_	_	NN	_	_	_	_	_
11	levels	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	uric	_	_	NN	_	_	_	_	_
14	acid	_	_	NN	_	_	_	_	_
15	excretion	_	_	NN	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	more	_	_	RBR	_	_	_	_	_
18	favorable	_	_	JJ	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	alkaline	_	_	JJ	_	_	_	_	_
21	urine	_	_	NN	_	_	_	_	_
22	than	_	_	IN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	acidic	_	_	JJ	_	_	_	_	_
25	urine	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	possible	_	_	JJ	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	elevation	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	urinary	_	_	JJ	_	_	_	_	_
11	pH	_	_	NN	_	_	_	_	_
12	caused	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	glycine	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	tryptophan	_	_	NN	_	_	_	_	_
17	supplementation	_	_	NN	_	_	_	_	_
18	enhanced	_	_	VBD	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	solubility	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	urinary	_	_	JJ	_	_	_	_	_
23	uric	_	_	NN	_	_	_	_	_
24	acid	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	thereby	_	_	RB	_	_	_	_	_
27	elevating	_	_	VBG	_	_	_	_	_
28	urinary	_	_	JJ	_	_	_	_	_
29	uric	_	_	NN	_	_	_	_	_
30	acid	_	_	NN	_	_	_	_	_
31	excretion	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	urate	_	_	JJ	_	_	_	_	_
34	clearance	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	provide	_	_	VBP	_	_	_	_	_
4	physiological	_	_	JJ	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	physicochemical	_	_	JJ	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	clinical	_	_	JJ	_	_	_	_	_
9	validation	_	_	NN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	use	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	citrate	_	_	NN	_	_	_	_	_
15	salt	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	some	_	_	DT	_	_	_	_	_
21	types	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	lithiasis	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Citrate	_	_	NN	_	_	_	_	_
2	salts	_	_	NNS	_	_	_	_	_
3	treatment	_	_	NN	_	_	_	_	_
4	substantially	_	_	RB	_	_	_	_	_
5	increased	_	_	VBD	_	_	_	_	_
6	urinary	_	_	JJ	_	_	_	_	_
7	pH	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	uric	_	_	JJ	_	_	_	_	_
12	acid	_	_	NN	_	_	_	_	_
13	lithiasis	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	however	_	_	RB	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	there	_	_	EX	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	no	_	_	DT	_	_	_	_	_
20	significant	_	_	JJ	_	_	_	_	_
21	change	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	amount	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	urinary	_	_	JJ	_	_	_	_	_
27	uric	_	_	NN	_	_	_	_	_
28	acid	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	mixture	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	amino	_	_	JJ	_	_	_	_	_
5	acids	_	_	NNS	_	_	_	_	_
6	might	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	superior	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	citrate	_	_	NN	_	_	_	_	_
11	salts	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	prevention	_	_	NN	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	hyperuricemia	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Herein	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	although	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	elevation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	urinary	_	_	JJ	_	_	_	_	_
8	pH	_	_	NN	_	_	_	_	_
9	induced	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	ingestion	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	glycine	_	_	NN	_	_	_	_	_
15	alone	_	_	RB	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	significant	_	_	JJ	_	_	_	_	_
19	compared	_	_	VBN	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	effects	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	placebo	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	glycine	_	_	NN	_	_	_	_	_
27	administration	_	_	NN	_	_	_	_	_
28	enhanced	_	_	VBN	_	_	_	_	_
29	uric	_	_	NN	_	_	_	_	_
30	acid	_	_	NN	_	_	_	_	_
31	excretion	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	urate	_	_	JJ	_	_	_	_	_
34	clearance	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	raising	_	_	VBG	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	possibility	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	other	_	_	JJ	_	_	_	_	_
41	mechanisms	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Urate	_	_	JJ	_	_	_	_	_
2	transporter	_	_	NN	_	_	_	_	_
3	1	_	_	CD	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	URAT1	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	primary	_	_	JJ	_	_	_	_	_
10	reabsorptive	_	_	JJ	_	_	_	_	_
11	urate	_	_	NN	_	_	_	_	_
12	transporter	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	targeted	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	pyrazinamide	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	reportedly	_	_	RB	_	_	_	_	_
20	disables	_	_	VBZ	_	_	_	_	_
21	glycine-induced	_	_	JJ	_	_	_	_	_
22	uricosuria	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Pyrazinamide	_	_	NNP	_	_	_	_	_
2	may	_	_	MD	_	_	_	_	_
3	reflect	_	_	VB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	enhanced	_	_	VBN	_	_	_	_	_
6	urate	_	_	JJ	_	_	_	_	_
7	reabsorption	_	_	NN	_	_	_	_	_
8	following	_	_	VBG	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	exchange	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	its	_	_	PRP$	_	_	_	_	_
13	active	_	_	JJ	_	_	_	_	_
14	metabolite	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	glycine	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	inhibit	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	reabsorptive	_	_	JJ	_	_	_	_	_
8	action	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	uric	_	_	NN	_	_	_	_	_
11	acid	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	which	_	_	WDT	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	induced	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	URAT1	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Further	_	_	JJR	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	needed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	elucidate	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	action	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	glycine	_	_	NN	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	URAT1	_	_	NNP	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	supplementation	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	tryptophan	_	_	NN	_	_	_	_	_
10	alone	_	_	RB	_	_	_	_	_
11	had	_	_	VBD	_	_	_	_	_
12	no	_	_	DT	_	_	_	_	_
13	influence	_	_	NN	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	urinary	_	_	JJ	_	_	_	_	_
16	pH	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	urinary	_	_	JJ	_	_	_	_	_
19	uric	_	_	NN	_	_	_	_	_
20	acid	_	_	NN	_	_	_	_	_
21	excretion	_	_	NN	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	urate	_	_	NN	_	_	_	_	_
24	clearance	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	effect	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	tryptophan	_	_	NN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	URAT1	_	_	NNP	_	_	_	_	_
8	might	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	structurally	_	_	RB	_	_	_	_	_
11	difficult	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	tryptophan	_	_	NN	_	_	_	_	_
14	might	_	_	MD	_	_	_	_	_
15	have	_	_	VB	_	_	_	_	_
16	exerted	_	_	VBN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	indirect	_	_	JJ	_	_	_	_	_
19	action	_	_	NN	_	_	_	_	_
20	against	_	_	IN	_	_	_	_	_
21	uric	_	_	JJ	_	_	_	_	_
22	acid	_	_	NN	_	_	_	_	_
23	elevation	_	_	NN	_	_	_	_	_
24	via	_	_	IN	_	_	_	_	_
25	its	_	_	PRP$	_	_	_	_	_
26	influence	_	_	NN	_	_	_	_	_
27	on	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	action	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	glycine	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Specifically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	tryptophan	_	_	NN	_	_	_	_	_
4	might	_	_	MD	_	_	_	_	_
5	promote	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	direct	_	_	JJ	_	_	_	_	_
8	action	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	glycine	_	_	NN	_	_	_	_	_
11	against	_	_	IN	_	_	_	_	_
12	uric	_	_	JJ	_	_	_	_	_
13	acid	_	_	NN	_	_	_	_	_
14	elevation	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	maximum	_	_	JJ	_	_	_	_	_
3	serum	_	_	NN	_	_	_	_	_
4	levels	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	glycine	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	tryptophan	_	_	NN	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	achieved	_	_	VBN	_	_	_	_	_
11	within	_	_	IN	_	_	_	_	_
12	an	_	_	DT	_	_	_	_	_
13	hour	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	ingestion	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	followed	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	rapid	_	_	JJ	_	_	_	_	_
22	decreases	_	_	NNS	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	amino	_	_	NN	_	_	_	_	_
26	acids	_	_	NNS	_	_	_	_	_
27	are	_	_	VBP	_	_	_	_	_
28	metabolized	_	_	VBN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Glycine	_	_	NNP	_	_	_	_	_
2	metabolizes	_	_	VBZ	_	_	_	_	_
3	various	_	_	JJ	_	_	_	_	_
4	end-products	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	namely	_	_	RB	_	_	_	_	_
7	glutathione	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	nucleic	_	_	JJ	_	_	_	_	_
10	acid	_	_	NN	_	_	_	_	_
11	bases	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	heme	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	creatine	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	bile	_	_	NN	_	_	_	_	_
18	acids	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	increases	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	urinary	_	_	JJ	_	_	_	_	_
5	creatinine	_	_	NN	_	_	_	_	_
6	excretion	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	creatinine	_	_	NN	_	_	_	_	_
9	clearance	_	_	NN	_	_	_	_	_
10	following	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	glycine	_	_	NN	_	_	_	_	_
13	challenge	_	_	NN	_	_	_	_	_
14	suggest	_	_	VBP	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	glycine	_	_	NN	_	_	_	_	_
17	might	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	partially	_	_	RB	_	_	_	_	_
20	absorbed	_	_	VBN	_	_	_	_	_
21	back	_	_	RB	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	metabolized	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	creatinine	_	_	NN	_	_	_	_	_
26	through	_	_	IN	_	_	_	_	_
27	creatine	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Conversely	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	urinary	_	_	JJ	_	_	_	_	_
5	parameters	_	_	NNS	_	_	_	_	_
6	did	_	_	VBD	_	_	_	_	_
7	not	_	_	RB	_	_	_	_	_
8	change	_	_	VB	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	response	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	simultaneous	_	_	JJ	_	_	_	_	_
14	supplementation	_	_	NN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	glycine	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	tryptophan	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	suggesting	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	suppression	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	conversion	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	glycine	_	_	NN	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	creatinine	_	_	NN	_	_	_	_	_
30	by	_	_	IN	_	_	_	_	_
31	tryptophan	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	increases	_	_	NNS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	serum	_	_	NN	_	_	_	_	_
9	glycine/creatinine	_	_	NN	_	_	_	_	_
10	ratio	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	urinary	_	_	JJ	_	_	_	_	_
13	glycine	_	_	NN	_	_	_	_	_
14	excretion	_	_	NN	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	more	_	_	RBR	_	_	_	_	_
17	pronounced	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	response	_	_	NN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	supplementation	_	_	NN	_	_	_	_	_
22	with	_	_	IN	_	_	_	_	_
23	glycine	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	tryptophan	_	_	NN	_	_	_	_	_
26	than	_	_	IN	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	glycine	_	_	NN	_	_	_	_	_
29	alone	_	_	RB	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Further	_	_	JJR	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	required	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	clarify	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	mechanism	_	_	NN	_	_	_	_	_
9	underlying	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	contribution	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	tryptophan	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	effects	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	glycine	_	_	NN	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	uric	_	_	NN	_	_	_	_	_
21	acid	_	_	NN	_	_	_	_	_
22	excretion	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	limitations	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	current	_	_	JJ	_	_	_	_	_
7	clinical	_	_	JJ	_	_	_	_	_
8	study	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	modest	_	_	JJ	_	_	_	_	_
12	sample	_	_	NN	_	_	_	_	_
13	size	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	n	_	_	NN	_	_	_	_	_
16	=	_	_	SYM	_	_	_	_	_
17	16	_	_	CD	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	might	_	_	MD	_	_	_	_	_
20	have	_	_	VB	_	_	_	_	_
21	reduced	_	_	VBN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	statistical	_	_	JJ	_	_	_	_	_
24	power	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	increased	_	_	VBD	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	risk	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	type	_	_	NN	_	_	_	_	_
31	II	_	_	NN	_	_	_	_	_
32	error	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	particularly	_	_	RB	_	_	_	_	_
35	regarding	_	_	VBG	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	statistical	_	_	JJ	_	_	_	_	_
38	differences	_	_	NNS	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	multiple	_	_	JJ	_	_	_	_	_
41	comparisons	_	_	NNS	_	_	_	_	_
42	between	_	_	IN	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	glycine	_	_	NN	_	_	_	_	_
45	and	_	_	CC	_	_	_	_	_
46	glycine	_	_	NN	_	_	_	_	_
47	+	_	_	SYM	_	_	_	_	_
48	tryptophan	_	_	NN	_	_	_	_	_
49	groups	_	_	NNS	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	current	_	_	JJ	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	included	_	_	VBD	_	_	_	_	_
7	only	_	_	RB	_	_	_	_	_
8	male	_	_	JJ	_	_	_	_	_
9	subjects	_	_	NNS	_	_	_	_	_
10	because	_	_	IN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	known	_	_	VBN	_	_	_	_	_
14	effects	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	sex	_	_	NN	_	_	_	_	_
17	differences	_	_	NNS	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	serum	_	_	NN	_	_	_	_	_
20	uric	_	_	JJ	_	_	_	_	_
21	acid	_	_	NN	_	_	_	_	_
22	levels	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Further	_	_	JJR	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	therefore	_	_	RB	_	_	_	_	_
5	needed	_	_	VBN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	although	_	_	IN	_	_	_	_	_
8	our	_	_	PRP$	_	_	_	_	_
9	preliminary	_	_	JJ	_	_	_	_	_
10	findings	_	_	NNS	_	_	_	_	_
11	suggested	_	_	VBD	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	there	_	_	EX	_	_	_	_	_
14	were	_	_	VBD	_	_	_	_	_
15	no	_	_	DT	_	_	_	_	_
16	effective	_	_	JJ	_	_	_	_	_
17	differences	_	_	NNS	_	_	_	_	_
18	between	_	_	IN	_	_	_	_	_
19	males	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	females	_	_	NNS	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	response	_	_	NN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	glycine	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	tryptophan	_	_	NN	_	_	_	_	_
28	supplementation	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	data	_	_	NNS	_	_	_	_	_
31	not	_	_	RB	_	_	_	_	_
32	shown	_	_	VBN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_

